title: Comparison of rHuEpo plus rHuG-CSF and supportive care: apples to oranges.
authors.forename: Roberto
authors.initials: R
authors.lastname: Stasi
authors.forename: Sergio
authors.initials: S
authors.lastname: Amadori
authors.forename: Adrian C
authors.initials: AC
authors.lastname: Newland
authors.forename: Drew
authors.initials: D
authors.lastname: Provan
mesh_terms: D000740:Anemia / Q000150:complications; D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D004921:Erythropoietin / Q000627:therapeutic use*; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*; D010919:Placebos; D011788:Quality of Life; D011994:Recombinant Proteins; D012306:Risk; D016896:Treatment Outcome
chemical_list: D010919:Placebos; D011994:Recombinant Proteins; D004921:Erythropoietin; D016179:Granulocyte Colony-Stimulating Factor